Benitec Biopharma (BNTC) Operating Leases: 2019-2025
Historic Operating Leases for Benitec Biopharma (BNTC) over the last 5 years, with Mar 2025 value amounting to $613,000.
- Benitec Biopharma's Operating Leases rose 73.16% to $613,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $613,000, marking a year-over-year increase of 73.16%. This contributed to the annual value of $284,000 for FY2024, which is 49.19% down from last year.
- Per Benitec Biopharma's latest filing, its Operating Leases stood at $613,000 for Q1 2025, which was up 347.45% from $137,000 recorded in Q4 2024.
- In the past 5 years, Benitec Biopharma's Operating Leases ranged from a high of $954,000 in Q3 2021 and a low of $137,000 during Q4 2024.
- Its 3-year average for Operating Leases is $410,556, with a median of $423,000 in 2023.
- In the last 5 years, Benitec Biopharma's Operating Leases soared by 280.75% in 2022 and then tumbled by 67.61% in 2024.
- Benitec Biopharma's Operating Leases (Quarterly) stood at $911,000 in 2021, then decreased by 24.81% to $685,000 in 2022, then tumbled by 38.25% to $423,000 in 2023, then slumped by 67.61% to $137,000 in 2024, then spiked by 73.16% to $613,000 in 2025.
- Its Operating Leases stands at $613,000 for Q1 2025, versus $137,000 for Q4 2024 and $211,000 for Q3 2024.